12:00 AM
Jul 27, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zevalin ibritumomab tiuxetan regulatory update

Spectrum said FDA accepted for review the resubmission of an sBLA for Zevalin ibritumomab tiuxetan as consolidation therapy after remission induction in previously untreated patients with follicular B cell non-Hodgkin's lymphoma (NHL). The agency designated...

Read the full 151 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >